

# Resource Summary Report

Generated by [kravitz2](#) on Jul 31, 2026

## PE anti-human CD14

RRID:AB\_314187

Type: Antibody

### Proper Citation

BioLegend Cat# 301805, RRID:AB\_314187

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_314187](http://antibodyregistry.org/AB_314187)

**Proper Citation:** BioLegend Cat# 301805, RRID:AB\_314187

**Target Antigen:** CD14

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** PE anti-human CD14

**Description:** This monoclonal targets CD14

**Target Organism:** cynomolgus, rhesus, human

**Clone ID:** Clone M5E2

**Antibody ID:** AB\_314187

**Vendor:** BioLegend

**Catalog Number:** 301805

**Alternative Catalog Numbers:** 301806, 301850

**Record Creation Time:** 20250820T000306+0000

**Record Last Update:** 20250820T071334+0000

### Ratings and Alerts

No rating or validation information has been found for PE anti-human CD14.

No alerts have been found for PE anti-human CD14.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [kravitz2](#) .

Salgia NJ, et al. (2025) Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma. Cancer cell.

Hamdan F, et al. (2023) Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses. Molecular therapy oncolytics, 28, 264.

Li Y, et al. (2022) Macrophages activated by hepatitis B virus have distinct metabolic profiles and suppress the virus via IL-1 $\beta$  to downregulate PPAR $\gamma$  and FOXO3. Cell reports, 38(4), 110284.

Hamdan F, et al. (2021) Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. Journal for immunotherapy of cancer, 9(8).

Purvis GSD, et al. (2020) Inhibition of Bruton's TK regulates macrophage NF- $\kappa$ B and NLRP3 inflammasome activation in metabolic inflammation. British journal of pharmacology, 177(19), 4416.